Most Favored Nation drug pricing proposal aims to tie US medicine costs to lower European rates, but experts warn this approach could restrict patient access to lifesaving treatments, slow innovation, ...

Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, continues his conversation about launch failures, this time detailing unrealistic launch forecasts, ...

A new report from Reuters 1 details how the residents of Kalundborg, Denmark, are reacting to the news of the looming layoffs ...

Ryan Quigley, CEO of Inizio, explains the impact of advancements and innovations and how they’re making pharma more personalized.

Peter Rubin discusses how effective President Trump’s executive order could actually be against the factors that dictate drug pricing.

Ascletis Pharma reveals ASC47, a promising weight loss drug, shows over 56% greater body weight reduction when combined with ...

Eli Lilly halted a study on bimagrumab for Type 2 diabetes patients, focusing on weight loss and muscle mass preservation.

Pharma leaders embrace direct-to-consumer strategies, with 94% exploring DTC programs to enhance patient experience and ...

In today’s Pharmaceutical Executive Daily, we cover Glenmark’s billion-dollar exclusive licensing deal with Hengrui, Harmony ...

FDA approves Eli Lilly’s Inluriyo (imlunestrant) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after endocrine therapy.

Glenmark partners with Hengrui Pharma to develop Trastuzumab Rezetecan, enhancing its oncology pipeline and addressing unmet ...

Harmony Biosciences reveals disappointing results from the Phase III Reconnect study of ZYN002 for Fragile X Syndrome, ...